Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

E-068

Supelco

Everolimus solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C53H83NO14
Numéro CAS:
159351-69-6
Poids moléculaire :
958.22
Numéro MDL:
MFCD00929329
Code UNSPSC :
41116107
ID de substance PubChem :
329798983
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Niveau de qualité

300

Forme

liquid

Caractéristiques

(Snap-N-Spike®)

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in acetonitrile

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Conditions d'expédition

dry ice

Température de stockage

−70°C

InChI

1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

Clé InChI

HKVAMNSJSFKALM-GKUWKFKPSA-N

Informations sur le gène

human ... FKBP1A(2280)

Catégories apparentées

Description générale

Everolimus, sold under trade names including Zortress®, Certican, and Afinitor®, is an immunosuppressant drug used to prevent rejection of organ transplants and to treat renal cell cancer and other tumors. This Certified Spiking Solution® is suitable as starting material for calibrators, controls, or linearity standards for therapeutic drug monitoring or clinical and diagnostic testing of everolimus in patient whole blood samples by LC-MS/MS.

Application


  • Everolimus as a therapy for hepatoblastoma: Research demonstrates that Everolimus can induce autophagy-dependent ferroptosis in hepatoblastoma cells, highlighting its potential as a therapeutic agent in oncology research. This study provides insight into the mechanisms by which Everolimus can be utilized to target cancer cells through cell death pathways (Huang et al., 2024).

  • Understanding oral mucosal injuries from mTOR inhibitors: A new hypothesis posits that oral mucosal injuries associated with mTOR inhibitors like Everolimus result from disruptions in cellular stress and apoptotic pathways. This study underscores the importance of understanding side effects in the context of targeted therapy for conditions such as cancers and immunosuppression (Sonis and Villa, 2023).

  • Micellar formulation of Everolimus for neurological disorders: A stable micellar formulation of Everolimus (RAD001) has been developed for intracerebroventricular delivery, aimed at treating Alzheimer′s Disease and other neurological disorders. This formulation allows for direct brain administration, potentially enhancing the drug′s efficacy and safety profile (Gianessi et al., 2023).

  • Pharmacokinetics in epilepsy treatment: The population pharmacokinetics of Everolimus were studied in patients with seizures associated with focal cortical dysplasia. This research aids in understanding the drug′s behavior in a specific neurological context, providing a foundation for dosing adjustments and therapeutic monitoring (Park et al., 2023).

Informations légales

Afinitor is a registered trademark of Novartis AG
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zortress is a registered trademark of Novartis AG

Pictogrammes

FlameExclamation mark
GHS02,GHS07

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

35.6 °F - closed cup

Point d'éclair (°C)

2.0 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 6

1 of 6

Ascomycin solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

A-094

Ascomycin solution

Posaconazole solution 2.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

P-103

Posaconazole solution

IMD-0354 ≥98% (HPLC), solid

Sigma-Aldrich

I3159

IMD-0354

FK-506 monohydrate ≥98% (HPLC)

Sigma-Aldrich

F4679

FK-506 monohydrate

Rapamycin ≥95% (HPLC), powder

Sigma-Aldrich

553210

Rapamycin

Pazopanib

Sigma-Aldrich

CDS023580

Pazopanib

Ian T Meredith et al.
The American journal of cardiology, 113(7), 1117-1123 (2014-02-18)
In the randomized PLATINUM trial, the PROMUS Element platinum-chromium everolimus-eluting stent (PtCr-EES; Boston Scientific, Natick, Massachusetts) was noninferior to the XIENCE V cobalt-chromium everolimus-eluting stent (CoCr-EES; Boston Scientific and Abbott Vascular, Santa Clara, California) for the primary end point of
L M Neri et al.
Leukemia, 28(4), 739-748 (2013-07-31)
B-precursor acute lymphoblastic leukemia (B-pre ALL) is a malignant disorder characterized by the abnormal proliferation of B-cell progenitors. The prognosis of B-pre ALL has improved in pediatric patients, but the outcome is much less successful in adults. Constitutive activation of
Catherine Lombard-Bohas et al.
Bulletin du cancer, 101(2), 175-183 (2014-02-22)
Medical management of pancreatic neuroendocrine tumors has recently been improved by new molecules of which the mTOR inhibitor everolimus. If digestive neuroendocrine tumors are rare, the incidence is in constant increase and the prevalence in digestive cancers put them right
Masanori Taniwaki et al.
Journal of the American College of Cardiology, 63(16), 1617-1625 (2014-02-18)
The aim of the study was to investigate 4-year outcomes and predictors of repeat revascularization in patients treated with the Resolute zotarolimus-eluting stent (R-ZES) (Medtronic, Minneapolis, Minnesota) and XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, Abbott Park, Illinois) in the
Michael Cardamone et al.
The Journal of pediatrics, 164(5), 1195-1200 (2014-02-13)
To evaluate the efficacy and side effects of oral mammalian target of rapamycin (mTOR) inhibitors in children and adolescents with tuberous sclerosis complex (TSC) and intractable epilepsy or subependymal giant cell astrocytoma (SEGA). Single-center series of 13 children and adolescents
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique